A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
ensure patients have access to certain urgent-use com-
pounded medications, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Patient Access to Ur-
4
gent-Use Pharmacy Compounding Act of 2021’’. 
5
04:51 Jun 26, 2021
H3662
2 
•HR 3662 IH
SEC. 2. URGENT-USE COMPOUNDING FOR ADMINISTRA-
1
TION IN HOSPITALS OR OTHER CLINICAL 
2
SETTINGS. 
3
Section 503A(a) of the Federal Food, Drug, and Cos-
4
metic Act (21 U.S.C. 353a(a)) is amended— 
5
(1) in paragraph (1), by striking ‘‘or’’ at the 
6
end; 
7
(2) in paragraph (2)(B)(ii)(II), by striking the 
8
period at the end and inserting ‘‘; or’’; and 
9
(3) by adding at the end the following new 
10
paragraph: 
11
‘‘(3) notwithstanding the requirement in the 
12
matter preceding paragraph (1) that the drug prod-
13
uct is compounded for an identified individual pa-
14
tient based on a valid prescription order or notation 
15
described in such matter, is by a licensed pharmacist 
16
or licensed physician and the compounded drug 
17
product is compounded for distribution in limited 
18
quantities to a licensed prescriber for urgent admin-
19
istration to a patient in a hospital or other clinical 
20
setting, provided that all of the following are met: 
21
‘‘(A) The licensed prescriber certifies by 
22
notation on the order to the compounding phar-
23
macist or physician that the licensed prescriber 
24
has made reasonable attempts to obtain, and 
25
04:51 Jun 26, 2021
H3662
3 
•HR 3662 IH
has not been able to obtain, to address the ur-
1
gent medical need— 
2
‘‘(i) a drug product that is approved 
3
or authorized by the Food and Drug Ad-
4
ministration with the same active ingre-
5
dient and the same route of administra-
6
tion; or 
7
‘‘(ii) a drug product that is com-
8
pounded by an outsourcing facility in ac-
9
cordance with section 503B with the same 
10
active ingredient and the same route of ad-
11
ministration. 
12
‘‘(B) The compounded drug product is la-
13
beled with a beyond-use-date in accordance with 
14
applicable United States Pharmacopeia stand-
15
ards. 
16
‘‘(C) The licensed pharmacist or licensed 
17
physician marks the packaging of the com-
18
pounded drug product with text— 
19
‘‘(i) indicating that the drug product 
20
is provided to the hospital or other clinical 
21
setting only for urgent administration to a 
22
patient; and 
23
‘‘(ii) requesting that the hospital or 
24
other clinical setting provide to the com-
25
04:51 Jun 26, 2021
H3662
4 
•HR 3662 IH
pounding pharmacist or physician the 
1
records that identify the patient or pa-
2
tients to whom the drug products were ad-
3
ministered within— 
4
‘‘(I) 7 days of each such patient 
5
receiving such medication; or 
6
‘‘(II) 7 days of each such patient 
7
being discharged. 
8
‘‘(D) Upon receipt of records requested 
9
pursuant to subparagraph (C)(ii), the licensed 
10
pharmacist or licensed physician ensures that 
11
the patient information in such records is 
12
linked with the respective order. 
13
‘‘(E) The licensed pharmacist or licensed 
14
physician reports adverse events associated with 
15
the compounded drug product as soon as pos-
16
sible but no later than 15 days after becoming 
17
aware of such events to the MedWatch Adverse 
18
Event Reporting program of the Food and 
19
Drug Administration (or any successor pro-
20
gram).’’. 
21
04:51 Jun 26, 2021
H3662
5 
•HR 3662 IH
SEC. 3. COMPOUNDING FOR SHORTAGES FOR ADMINISTRA-
1
TION IN HOSPITALS OR OTHER CLINICAL 
2
SETTINGS. 
3
Paragraph (2) of section 503A(b) of the Federal 
4
Food, Drug, and Cosmetic Act (21 U.S.C. 353a(b)(2)) is 
5
amended to read as follows: 
6
‘‘(2) DEFINITION.—For purposes of paragraph 
7
(1)(D), the term ‘essentially a copy of a commer-
8
cially available drug product’ does not include— 
9
‘‘(A) a drug product in which there is a 
10
change, made for an identified individual pa-
11
tient, which produces for that patient a signifi-
12
cant difference, as determined by the pre-
13
scribing practitioner, between the compounded 
14
drug and the comparable commercially available 
15
drug product; or 
16
‘‘(B) a drug product that meets each of 
17
the following conditions: 
18
‘‘(i) At the time of compounding, dis-
19
tribution, or dispensing, the drug product 
20
appears on— 
21
‘‘(I) the drug shortage list in ef-
22
fect under section 506E; or 
23
‘‘(II) the drug shortage list main-
24
tained by the American Society of 
25
Hospital Pharmacists. 
26
04:51 Jun 26, 2021
H3662
6 
•HR 3662 IH
‘‘(ii) If the drug product is not com-
1
pounded for an identified individual patient 
2
based on a valid prescription order or nota-
3
tion, notwithstanding such requirement in 
4
the matter preceding paragraph (1) of sub-
5
section (a), then the drug product— 
6
‘‘(I) is labeled in accordance sub-
7
paragraphs (B) and (C) of subsection 
8
(a)(3); and 
9
‘‘(II) is documented by the 
10
compounding pharmacist or physician 
11
in accordance with subparagraphs (D) 
12
and (E) of subsection (a)(3).’’. 
13
Æ 
04:51 Jun 26, 2021
H3662
